DAWEX/CEA
28.5.2024 09:31:30 CEST | Business Wire | Press release
Dawex and CEA today announced that they have signed a partnership agreement to create a joint Research & Development Laboratory. Aiming at conceiving and developing technological solutions to catalyze truly impactful innovations in the field of data ecosystem, the collaboration between the CEA and Dawex will feed responses to global industry challenges to shape a more sustainable & resilient future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528953935/en/
The creation of secure, trusted and interoperable data ecosystems and data spaces has become crucial in fostering trusted artificial intelligence and realizing a sustainable and digital society. Data exchange and data circulation are at the forefront in boosting transformative solutions such as Generative AI, while pushing the boundaries of innovation thanks to Privacy Enhancing Technologies integration —ultimately making such disruptive technologies accessible to customers.
Since its inception, Dawex has been investing in Research & Development, in order to bring the perfect conditions for secure, trustworthy, sovereign and compliant data exchange. Dawex will bring to this collaboration its extensive and proven expertise in secure data exchange, data governance, interoperability, standards & norms. Through active engagements in developing the most advanced data exchange solutions and contributing to regulations, norms & de facto standards, Dawex has been demonstrating its leadership as a strategic market player, notably by powering the largest number of European data spaces.
The CEA participates in accelerating industry transformation with programs on the factory of the future, digital twins, artificial intelligence, and digital trust. It ultimately contributes to building a powerful innovation ecosystem guided by the values of social and environmental responsibility.
“Innovation and Research have been in Dawex DNA since Day-1. We are committed to advancing data exchange matters and address forward looking data challenges, delivering the most sophisticated data exchange technology” said Fabrice Tocco, co-CEO at Dawex. “We are extremely happy to collaborate with the CEA and co-innovate to bring the next-generation innovations that will transform data exchange,” concluded Mr Tocco.
”Data exchange plays a major role in the industry transformation that France and Europe are facing today. This leads CEA to partner with Dawex as a leading company in the field of data exchange and data ecosystems”, declared Alexandre Bounouh, CEO of CEA List institute. “Creating together a common R&D laboratory will enable us to bring thorough and trusted digital solutions to the industry with one objective in mind: to accelerate transitions and among them energy & climate ones. We are delighted to pursue this ambition with Dawex”.
About Dawex
Dawex is the leader in Data Exchange solutions to distribute or share data products, with trust, for any business case, in compliance with data regulations. With Dawex Data Exchange technology, organizations create data ecosystems and data spaces such as Corporate Data Hubs, Industry Data Hubs and Data Marketplaces to address economic, environmental and decarbonation challenges. At the invitation of the United Nations, Dawex joins the Data expert group of the United Nations Environment Program. Awarded Technology Pioneer by the World Economic Forum, Dawex is also the initiator of an international standardization program on Trusted Data Transaction. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
About CEA
The CEA is a major research organisation working in the best interests of the French State, its economy and citizens. Thanks to its strong roots in fundamental research, it is able to provide tangible solutions to meet their needs in four key fields: low-carbon energy, digital technologies, technologies for medicine of the future, defence and national security.
As the world's leading innovator among public research organisations (Clarivate 2024), the CEA acts as a catalyst and accelerator of innovation for French industry. It helps businesses in all sectors be more competitive, creating high-performance products that stand out from the crowd and developing trail-blazing solutions that lead to changes in society. The CEA deploys this dynamic in all regions of France aiding local partners to innovate themselves, thus helping to create sustainable value and jobs nationwide, tailored to meet actual industry needs. At the same time, it supports the development of its 250 start-ups, agile vectors for transferring the disruptive technology and knowledge developed at CEA laboratories to industry. More information: https://www.cea.fr/english
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528953935/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom